<DOC>
	<DOCNO>NCT00970216</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability antiviral efficacy telbivudine maintain suppression hepatitis B virus ( HBV ) DNA ( &lt; =300 copies/ml 60IU/ml , undetectable current polymerase chain reaction ( PCR ) - base assay ) HBeAg positive/negative patient physician 's general practice .</brief_summary>
	<brief_title>Study Telbivudine Chronic Hepatitis B</brief_title>
	<detailed_description>Primary objective : To evaluate antiviral efficacy telbivudine maintain suppression HBV DNA ( &lt; =300 copies/ml 60 IU/ml , undetectable current PCR-based assay ) HBeAg positive patient Week 24 Week 48 . Methodology : This open-label , prospective , observational , single-center single arm post marketing surveillance study . Number patient : It estimate enroll 240 intent-to-treat patient Taiwan . Population : Male female patient , least 18 year age diagnose chronic hepatitis B liver disease telbivudine prescribe physician base clinical justification . And patient able communicate well , provide write informed consent , willing participate entire study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>1 . Male female , least 18 year age . 2 . Documented chronic hepatitis B define follow : Clinical history compatible chronic hepatitis B. Detectable serum hepatitis B surface antigen &gt; = 6 month screen visit , either HBeAg positive negative . 3 . Willing able comply observational drug regimen study requirement . 4 . Willing able provide write informed consent participate study . 1 . Females pregnant , intend become pregnant breast feeding . 2 . Patients coinfection hepatitis C virus , hepatitis D virus human immunodeficiency virus . 3 . Patients hypersensitivity telbivudine excipients . 4 . One know primary secondary cause liver disease hepatitis B ( e.g. , alcoholism , steatohepatitis , autoimmune hepatitis , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's disease , congenital metabolic condition affect liver , congestive heart failure severe cardiopulmonary disease ) . Gilbert 's syndrome DubinJohnson syndrome exclude patient participation trial . 5 . Enrolled planning enrol another clinical trial investigational agent participate study . 6 . Unable receive safety tolerability assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HBV DNA non-detectability</keyword>
</DOC>